Internal Medicine, Hematology & Oncology · Walnut Creek, CA
NPI
1750365953
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
500 Lennon Ln
Walnut Creek, CA, 94598
Phone (925) 939-9610
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.7M
224,662 services
Medicare patients, 2024
473
Average age 77
Drug cost, 2024
$2.5M
1,052 prescriptions
Company payments, 2025
$9,827
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Diana Superfin was code J1439 (injection, ferric carboxymaltose, 1 mg), 57,000 times for 38 patients. In total Diana Superfin billed 224,662 services in 128 codes, and Medicare paid $2.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-09-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 57,000 | 38 | $0.87 | $49K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 16,300 | 19 | $2.35 | $38K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 15,300 | 20 | $0.11 | $1,700 |
| J0897 Injection, denosumab, 1 mg | Office | 8,400 | 53 | $20.57 | $173K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 5,600 | 36 | $0.10 | $573 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,000 | 23 | $0.68 | $1,352 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,974 | 27 | $0.09 | $175 |
| 99215 Office E&M - Established | Office | 1,050 | 321 | $164.24 | $172K |
| 99214 Office E&M - Established | Office | 629 | 214 | $119.73 | $75K |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 528 | 16 | $106.40 | $56K |
| 96375 Injection Administration | Office | 450 | 74 | $16.06 | $7,226 |
| 96372 Injection Administration | Office | 356 | 101 | $13.64 | $4,856 |
| 96413 Chemotherapy Administration | Office | 296 | 36 | $141.57 | $42K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 199 | 38 | $5.16 | $1,028 |
| 96365 Intravenous Infusion, Hydration | Office | 162 | 60 | $65.01 | $11K |
By year: 2022 $3.6M for 204,539 services; 2023 $3.4M for 236,013 services; 2024 $2.7M for 224,662 services.
Medicare prescription drug claims, 2024
In 2024, the drug Diana Superfin prescribed most often to Medicare patients was Aranesp (Darbepoetin Alfa In Polysorbat), with 75 prescriptions and refills. In total Diana Superfin wrote 1,052 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Aranesp Darbepoetin Alfa In Polysorbat | 75 | 75 | 17 | $208K |
| Eliquis Apixaban | 72 | 88 | 16 | $52K |
| Neulasta Onpro Pegfilgrastim | 55 | 55 | 14 | $347K |
| Exemestane Generic | 45 | 65 | Under 11 | $1,366 |
| Pantoprazole Sodium Generic | 39 | 82 | 15 | $546 |
| Prednisone Generic | 39 | 49 | Under 11 | $168 |
| Abiraterone Acetate Generic | 32 | 36 | Under 11 | $30K |
| Anastrozole Generic | 29 | 85 | 11 | $699 |
| Letrozole Generic | 24 | 66 | Under 11 | $719 |
| Hydroxyurea Generic | 23 | 42 | Under 11 | $715 |
| Xarelto Rivaroxaban | 22 | 42 | Under 11 | $23K |
| Acyclovir Generic | 21 | 34 | Under 11 | $213 |
| Xgeva Denosumab | 20 | 20 | Under 11 | $62K |
| Lynparza Olaparib | 20 | 20 | Under 11 | $177K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 18 | 24 | Under 11 | $28.64 |
Brand drugs: 463 claims; generic drugs: 589 claims; opioid claims: 26.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Diana Superfin $9,827 ($9,827 in general payments such as food, travel and fees) from 55 companies. The largest payer was Avyxa Pharma, LLC with $3,678.
| Company | Payments | Amount |
|---|---|---|
| Avyxa Pharma, LLC | 5 | $3,678 |
| GlaxoSmithKline, LLC. GSK | 15 | $1,363 |
| AstraZeneca Pharmaceuticals LP AZN | 15 | $444 |
| Janssen Biotech, Inc. JNJ | 16 | $375 |
| Pfizer Inc. PFE | 18 | $345 |
| E.R. Squibb & Sons, L.L.C. BMY | 25 | $332 |
| Celgene Corporation BMY | 20 | $273 |
| Merck Sharp & Dohme LLC MRK | 9 | $259 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $233 |
| Daiichi Sankyo Inc. 4568.T | 9 | $211 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.